Clinical Trials Logo

Central Nervous System Neoplasms clinical trials

View clinical trials related to Central Nervous System Neoplasms.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT05308407 Suspended - Exercise Clinical Trials

POWER UP: Participating Online While Exercising to Recover Using Play

Start date: May 4, 2022
Phase: N/A
Study type: Interventional

We will conduct a two-phase study. The first phase is to adapt and develop an active video game (AVG)-centered lifestyle physical activity (PA) intervention (POWER UP) for adolescents and young adults (AYA) with central nervous system tumors. The second phase is to test the feasibility and preliminary efficacy of a 12-week virtually delivered, group-based active video game-centered lifestyle physical activity intervention on function and quality of life in AYAs (aged 15-39) who are ≤1-year post-surgery for a central nervous system tumor. This population is at very high-risk for steep functional decline.

NCT ID: NCT00935090 Suspended - Lymphoma Clinical Trials

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Start date: September 2009
Phase: N/A
Study type: Interventional

RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.

NCT ID: NCT00003067 Suspended - Clinical trials for Brain and Central Nervous System Tumors

Biological Therapy in Treating Patients With Primary or Advanced Glioma

Start date: July 1997
Phase: Phase 2
Study type: Interventional

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells in patients with primary or advanced glioma. PURPOSE: Clinical trial to study the effectiveness of biological therapy with interleukin-2 and lymphokine-activated killer cells in treating patients who have primary, recurrent, or refractory malignant glioma.